Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Multicentre, Open Label Study to Assess the Efficacy and Safety of Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients With EGFR PACC Mutation or EGFR l861q Mutation

NCT06956001 is registered in ClinicalTrials.gov with Allist Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06956001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06956001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Multicentre, Open Label Study to Assess the Efficacy and Safety of Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients With EGFR PACC Mutation or EGFR l861q Mutation
Lead sponsor
Allist Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
November 19, 2024
Completion date
July 31, 2028
Enrollment
300 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

egfr, nsclc (advanced non-small cell lung cancer)